Background: Brain metastases (BMs) frequently occur in cancer patients, and stereotactic radiation therapy (SRT) is a preferred treatment option. In this retrospective study, we analyzed patients treated by SRT for a single BM during their first SRT session and we compared two subgroups: “Cohort 1” with patients did not undergo cerebral re-irradiation and “Cohort 2” with patients received at least one subsequent SRT session for cerebral recurrence. Methods: We included patients who received SRT for a single BM between January 2010 and June 2020. Cohort 1 comprised 152 patients, and Cohort 2 had 46 patients. Results: Cohort 2 exhibited younger patients with higher Karnofsky performance status (KPS). Median overall survival was considerably longer in Cohort 2 (21.8 months) compared to Cohort 1 (6.1 months). Local and cerebral recurrence rates were significantly higher in Cohort 2 (p< 0.001), attributed to patient selection and longer survival. The combined score of age and KPS proved to be a predictive factor for survival, with patients under 65 years of age and KPS > 80 showing the best survival rates in the overall population. Conclusion: This retrospective study highlights that the combined score of age and KPS can predict better survival, especially for patients under 65 years with a KPS score above 80. Further research involving larger and more diverse populations is essential to validate and expand upon these findings.
背景：脑转移瘤在癌症患者中常见，立体定向放射治疗是首选治疗方案之一。本研究回顾性分析了首次接受立体定向放射治疗的单发脑转移患者，并比较了两个亚组：未接受脑部再照射的"队列1"与因脑部复发至少接受过一次后续立体定向放射治疗的"队列2"。方法：纳入2010年1月至2020年6月期间接受立体定向放射治疗的单发脑转移患者，队列1包含152例患者，队列2包含46例患者。结果：队列2患者更年轻且卡氏功能状态评分更高。队列2中位总生存期（21.8个月）显著长于队列1（6.1个月）。队列2的局部复发率和脑部复发率显著更高（p<0.001），这与患者选择和较长生存期相关。年龄与卡氏功能状态评分组合被证实是生存期的预测因素，在总体人群中，年龄小于65岁且卡氏功能状态评分>80分的患者生存率最佳。结论：本回顾性研究表明年龄与卡氏功能状态评分组合可预测更佳生存期，特别是对于年龄小于65岁且卡氏功能状态评分高于80分的患者。未来需要通过更大规模、更多样化人群的研究来验证和拓展这些发现。
肿瘤(癌症)患者之家